The technical area of the Securities Commission ruled that Oncoclínicas controlling shareholders need not launch a public share offer. Minority shareholders contest the opinion and plan an appeal.
Technical Opinion No. 20/2026, signed by the Superintendence of Securities Registration on the afternoon of June 30, exempted the block linked to Centaurus Capital from the obligation to carry out a public offer.
Minority shareholders claim there was a relevant change of control and that the process was conducted with restrictions on adversarial proceedings, including short deadlines and difficulties accessing information.
The decision involves an estimated impact of up to R$ 6 billion. Criticisms regarding possible influence of former CVM members and conflicts of interest were sent to the Comptroller General of the Union.
Other investigations into information disclosed by the company since the IPO continue in distinct areas of the authority.